Inhibitors of poly-ADP-ribose polymerase (PARP) family proteins are currently in clinical trials as cancer therapeutics, yet the specificity of many of these compounds is unknown. Here we evaluated a series of 185 small-molecule inhibitors, including research reagents and compounds being tested clinically, for the ability to bind to the catalytic domains of 13 of the 17 human PARP family members including the tankyrases, TNKS1 and TNKS2. Many of the best-known inhibitors, including TIQ-A, 6(5H)-phenanthridinone, olaparib, ABT-888 and rucaparib, bound to several PARP family members, suggesting that these molecules lack specificity and have promiscuous inhibitory activity. We also determined X-ray crystal structures for five TNKS2 ligand complexes and four PARP14 ligand complexes. In addition to showing that the majority of PARP inhibitors bind multiple targets, these results provide insight into the design of new inhibitors.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hottiger, M.O., Hassa, P.O., Lüscher, B., Schüler, H. & Koch-Nolte, F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem. Sci. 35, 208–219 (2010).
Amé, J.C., Spenlehauer, C. & de Murcia, G. The PARP superfamily. Bioessays 26, 882–893 (2004).
Sugimura, T., Fujimura, S., Hasegawa, S. & Kawamura, Y. Polymerization of the adenosine 5′-diphosphate ribose moiety of NAD by rat liver nuclear enzyme. Biochim. Biophys. Acta 138, 438–441 (1967).
Otto, H. et al. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics 6, 139 (2005).
Kleine, H. et al. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol. Cell 32, 57–69 (2008).
Hassa, P.O. & Hottiger, M.O. The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases. Front. Biosci. 13, 3046–3082 (2008).
Yélamos, J., Schreiber, V. & Dantzer, F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol. Med. 14, 169–178 (2008).
Calabrese, C.R. et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. 96, 56–67 (2004).
Bryant, H.E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
Ashworth, A. Drug resistance caused by reversion mutation. Cancer Res. 68, 10021–10023 (2008).
Jagtap, P. & Szabo, C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 4, 421–440 (2005).
Kauppinen, T.M. & Swanson, R.A. The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience 145, 1267–1272 (2007).
Strosznajder, R.P., Czubowicz, K., Jesko, H. & Strosznajder, J.B. Poly(ADP-ribose) metabolism in brain and its role in ischemia pathology. Mol. Neurobiol. 41, 187–196 (2010).
Ba, X. & Garg, N.J. Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. Am. J. Pathol. 178, 946–955 (2011).
Smith, S., Giriat, I., Schmitt, A. & de Lange, T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 282, 1484–1487 (1998).
McCabe, N. et al. Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene 28, 1465–1470 (2009).
Huang, S.M. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614–620 (2009).
Purnell, M.R. & Whish, W.J. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem. J. 185, 775–777 (1980).
Papeo, G. et al. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity? Expert Opin Ther Pat 19, 1377–1400 (2009).
Fong, P.C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).
Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235–244 (2010).
Carden, C.P., Yap, T.A. & Kaye, S.B. PARP inhibition: targeting the Achilles′ heel of DNA repair to treat germline and sporadic ovarian cancers. Curr. Opin. Oncol. 22, 473–480 (2010).
Frye, S.V. The art of the chemical probe. Nat. Chem. Biol. 6, 159–161 (2010).
Ruf, A., Mennissier de Murcia, J., de Murcia, G. & Schulz, G.E. Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken. Proc. Natl. Acad. Sci. USA 93, 7481–7485 (1996).
Bell, C.E. & Eisenberg, D. Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry 35, 1137–1149 (1996).
Vedadi, M. et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl. Acad. Sci. USA 103, 15835–15840 (2006).
Niesen, F.H., Berglund, H. & Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212–2221 (2007).
Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 104, 20523–20528 (2007).
Plummer, R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin. Cancer Res. 16, 4527–4531 (2010).
Pellicciari, R. et al. Towards new neuroprotective agents: design and synthesis of 4H-thieno[2,3-c] isoquinolin-5-one derivatives as potent PARP-1 inhibitors. Farmaco 58, 851–858 (2003).
Chiarugi, A. et al. Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia. J. Pharmacol. Exp. Ther. 305, 943–949 (2003).
Hans, C.P. et al. Thieno[2,3-c]isoquinolin-5-one, a potent poly(ADP-ribose) polymerase inhibitor, promotes atherosclerotic plaque regression in high-fat diet-fed apolipoprotein E-deficient mice: effects on inflammatory markers and lipid content. J. Pharmacol. Exp. Ther. 329, 150–158 (2009).
Lehtiö, L. et al. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J. Med. Chem. 52, 3108–3111 (2009).
Karlberg, T. et al. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. J. Med. Chem. 53, 5352–5355 (2010).
Karlberg, T., Hammarström, M., Schütz, P., Svensson, L. & Schüler, H. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888. Biochemistry 49, 1056–1058 (2010).
Lehtiö, L. et al. Zinc binding catalytic domain of human tankyrase 1. J. Mol. Biol. 379, 136–145 (2008).
Iwashita, A. et al. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors. FEBS Lett. 579, 1389–1393 (2005).
Yu, M. et al. PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene 24, 1982–1993 (2005).
Chou, H.Y., Chou, H.T. & Lee, S.C. CDK-dependent activation of poly(ADP-ribose) polymerase member 10 (PARP10). J. Biol. Chem. 281, 15201–15207 (2006).
Citarelli, M., Teotia, S. & Lamb, R.S. Evolutionary history of the poly(ADP-ribose) polymerase gene family in eukaryotes. BMC Evol. Biol. 10, 308 (2010).
Edwards, A.M. et al. Too many roads not taken. Nature 470, 163–165 (2011).
Ringner, M. What is principal component analysis? Nat. Biotechnol. 26, 303–304 (2008).
The Structural Genomics Consortium is a registered charity (no. 1097737) that receives funds from the Canadian Institutes for Health Research, the Canada Foundation for Innovation, Genome Canada through the Ontario Genomics Institute, GlaxoSmithKline, Karolinska Institutet, the Knut and Alice Wallenberg Foundation, the Ontario Innovation Trust, the Ontario Ministry for Research and Innovation, Merck & Co., Inc., the Novartis Research Foundation, the Swedish Agency for Innovation Systems, the Swedish Foundation for Strategic Research and the Wellcome Trust. The study was also supported by grant RBc08-0014 from the Swedish Foundation for Strategic Research.
N.M., E.P. and Å.F. are employees of GE Healthcare, which manufactures and markets the Biacore T-200 instrument that was used in the study.
About this article
Cite this article
Wahlberg, E., Karlberg, T., Kouznetsova, E. et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 30, 283–288 (2012). https://doi.org/10.1038/nbt.2121
Discovery of new therapeutic redox targets for cardioprotection against ischemia/reperfusion injury and heart failure
Free Radical Biology and Medicine (2021)
Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)
Expert Opinion on Therapeutic Patents (2021)
Current Opinion in Obstetrics & Gynecology (2021)
Journal of Biological Chemistry (2021)